Multimedia News Request a Demo Contact Us Join Our Email List Home

GlucoStabilizer®

News

Medical Decision Network (MDN) Expands Technology License to Computerized Subcutaneous Insulin Program  

GlucoStablizer® Interface with Cloverleaf Passes HCA Certification

GlucoStabilizer is currently being used in The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial.
Medical Decision Network Acquires GlucoStabilizer® from Alere Informatics Solutions

 


 

Medical Decision Network (MDN) Expands Technology License to Computerized Subcutaneous Insulin Program Decision Expands MDN’s Access to Technology for Glycemic Control

 

Charlottesville, VA - January 8, 2015 - Medical Decision Network, LLC  ( MDN ) announced today an expansion of its license with Indiana University (IU) Health for the in-patient management of hyperglycemia.  IU Health has developed and deployed within their health system a computerized solution, GlucoStabilizer® Subcutaneous Insulin Program (CGS-SQ ), to manage the subcutaneous delivery of insulin to hospital patients suffering from elevated blood sugar. MDN is the first company granted a license to this program which has been in place at IU Health since 2008.

 

According to Greg Menke, President and CEO of MDN, the technology embedded in this license addresses an ever increasing clinical problem. “Patients presenting to the hospital with elevated blood sugar and the absence of a diagnosis of diabetes are at levels estimated to be at 40 percent,” according to Mr. Menke.  “Having access to this technology will allow our GlucoStabilizer customers the much needed ability to provide for the full maintenance and control of hyperglycemia from admission to discharge,” he adds.

 

Previously reported research by IU Health indicated that utilization of the CGS-SQ resulted in acceptable levels of glucose protocol compliance throughout the patient’s hospital encounter without any increased risk of hypoglycemia. “We have worked on the clinical issue of glycemic control for quite some time,” says JoAnn Brooks, Vice President System Quality and Safety for IU Health.  “Our institution has been at the forefront when it comes to glycemic control for many years and our technology has been the key to our success. We are pleased that MDN will now expand their use of our technology to include the subcutaneous management of insulin. It will give their customers a complete solution when it comes to glycemic control.”   

 

The CGS-SQ functionality is expected to be launched immediately following 510K clearance notification from the FDA.

 


 

GlucoStablizer® Interface with Cloverleaf Passes HCA Certification

Interface was tested, validated and signed off by Henrico Medical Center, Richmond, VA

 

Charlottesville, VA –June 19, 2014- Medical Decision Network, LLC (MDN), announced today that the GlucoStabilizer® software-guided insulin dosing system has passed HCA Certification. The new product will receive ADT from Meditech and send CMI/LAD results to MT. The interface was tested, validated and signed off by Henrico Medical Center in Richmond, Virginia.

 

Below are Cloverleaf Product details:
 

Cloverleaf Interface Information

  • Adt_glur_out

  • Oeadm_glur_in

Product Support Information

  • Facility Supported

Ordering Interface Information

  • The interface request process will vary depending on the company affiliation;

  • HCA facilities requesting an existing interface will complete the Cloverleaf Request Form.

  • For all Non-HCA facilities, the assigned Account Executive from Parallon must submit a Statement of Work (SOW) on behalf of the requesting facility.

Other Information

  • Interface requires facility to have the Oeadm connection in Meditech NMI


 

GlucoStabilizer is currently being used in The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial.

This trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.

Eligible subjects must be within 12 hours of stroke symptom onset and have diabetes and glucose concentrations of over 110 mg/dL on initial evaluation. The enrolling sites will include the Neurological Emergencies Treatment Trials (NETT) sites as well as non NETT sites from all over the United States. The study will evaluate the safety and efficacy of targeted glucose control (treatment group - IV insulin with target 80-130 mg/dl) verses control therapy of sub q insulin plus basal insulin with target glucose less than 180 mg/ dL. The primary outcome will be functional outcome at 3 months as measured by the modified Rankin Scale (mRS) Score. The primary safety outcome will be severe hypoglycemia defined as <40 mg/dL. Enrollment will occur over 3.5 - 4 years.

 

Click here for more information on the SHINE Trial on the Clinical Trials website.


 

Medical Decision Network Acquires GlucoStabilizer® from Alere Informatics Solutions

Insulin Dosing Management System helps stabilize glucose levels, reduce hypoglycemia and minimizes errors

 

Charlottesville, VA –April 17, 2014- Medical Decision Network, LLC (MDN), announced today that it has acquired the GlucoStabilizer® business from Alere Informatics Solutions. GlucoStabilizer® is a software-guided insulin dosing system, cleared by the U.S. Food and Drug Administration (FDA), and used in critical care applications to calculate the dose of intravenous (I.V.) insulin needed to effectively control and stabilize blood glucose levels while reducing hypoglycemia and reducing errors.

 

“MDN was the original owner of the GlucoStabilizer® technology, having licensed it from the Indiana University Health System in 2004,” said Greg Menke, president of MDN. “The technology was acquired by Alere in October of 2011, and the business unit was renamed Alere Informatics solutions. We are excited about re-acquiring the technology and continuing to work with our many valued users”, adds Menke.

 

Traditionally, critical care nurses use paper-based protocols to manually monitor and adjust I.V. insulin dosing. In Deadly Errors Made in Intensive Care1 of the 38,000 reported mistakes, insulin was the single most common medication associated with errors due to overdosing and underdosing. GlucoStabilizer® reduces these risks by automatically calculating complex protocols to determine proper IV insulin dosage; replacing multiple protocols and sliding scale efforts with a standardized process of individualized care; eliminating the tendency to not follow a paper insulin dosing protocol; and alerting nursing with audible and visual alarms to improve efficiency and timely dosing adjustments.

 

The GlucoStabilizer® software-guided system is easy to operate, runs on a hospital's existing computer system and can be interfaced with a hospital information system (HIS).  To date, more than 100,000 patients with more than 4,000,000 blood glucose readings have had their blood glucose levels controlled with GlucoStabilizer®.

 

© 2015. All rights reserved. GlucoStabilizer is a trademark of Indiana University Health, Inc. under license.